-
TSHA Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Taysha Gene Therapies (TSHA)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 160.29 mm | 160.29 mm | 160.29 mm | 160.29 mm | 160.29 mm | 160.29 mm |
Cash burn (monthly) | 5.02 mm | 552.25 k | 8.63 mm | 7.31 mm | 7.21 mm | 6.59 mm |
Cash used (since last report) | 23.27 mm | 2.56 mm | 40.04 mm | 33.92 mm | 33.42 mm | 30.55 mm |
Cash remaining | 137.01 mm | 157.73 mm | 120.25 mm | 126.37 mm | 126.87 mm | 129.74 mm |
Runway (months of cash) | 27.3 | 285.6 | 13.9 | 17.3 | 17.6 | 19.7 |
13F holders | Current |
---|---|
Total holders | 124 |
Opened positions | 32 |
Closed positions | 19 |
Increased positions | 44 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 316.82 bn |
Total shares | 199.97 mm |
Total puts | 24.00 k |
Total calls | 25.90 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 18.68 mm | $37.54 bn |
Avoro Capital Advisors | 18.65 mm | $37.49 bn |
Paul B Manning | 16.47 mm | $31.78 mm |
RTW Investments | 14.95 mm | $30.04 bn |
BlackRock | 13.52 mm | $27.18 bn |
Ra Capital Management | 10.87 mm | $21.85 bn |
VR Adviser | 9.00 mm | $18.09 bn |
Venrock Healthcare Capital Partners III | 9.00 mm | $16.83 mm |
Vanguard | 8.27 mm | $16.61 bn |
MS Morgan Stanley | 7.66 mm | $15.40 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 25 | Kamran Alam | Common Stock | Grant | Acquire A | No | No | 0 | 431,000 | 0.00 | 1,271,937 |
2 Jan 25 | Kamran Alam | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.85 | 431,000 | 797.35 k | 431,000 |
2 Jan 25 | Nagendran Sukumar | Common Stock | Grant | Acquire A | No | No | 0 | 324,500 | 0.00 | 1,222,343 |
2 Jan 25 | Nagendran Sukumar | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.85 | 324,500 | 600.33 k | 324,500 |
2 Jan 25 | Nolan Sean P. | Common Stock | Grant | Acquire A | No | No | 0 | 892,500 | 0.00 | 2,078,358 |
2 Jan 25 | Nolan Sean P. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.85 | 892,500 | 1.65 mm | 892,500 |
27 Jun 24 | Paul B Manning | Common Stock | Buy | Acquire P | No | No | 2.25 | 1,333,333 | 3.00 mm | 1,333,333 |
29 May 24 | Laura Sepp-Lorenzino | Common Stock | Grant | Acquire A | No | No | 0 | 49,220 | 0.00 | 49,220 |
29 May 24 | Laura Sepp-Lorenzino | Stock Option Common Stock | Grant | Acquire A | No | No | 3.17 | 98,440 | 312.05 k | 98,440 |